TCS-OX2-29
CAS: 372523-75-6
Ref. 3D-XPA52375
| 5mg | A consultar | ||
| 10mg | A consultar | ||
| 25mg | A consultar | ||
| 50mg | A consultar | ||
| 100mg | A consultar |
Informação sobre produto
- 1-Butanone, 1-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-3,3-dimethyl-2-[(4-pyridinylmethyl)amino]-, (2S)-
- (2S)-2-(4-Pyridylmethylamino)-1-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)-3,3-dimethylbutan-1-one
- (2S)-1-(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-3,3-dimethyl-2-[(4-pyridinylmethyl)amino]-1-butanone
- Isoquinoline, 2-[(2S)-3,3-dimethyl-1-oxo-2-[(4-pyridinylmethyl)amino]butyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-
- TCS-OX 2-29
TCS-OX2-29 is a novel nicotinic acetylcholine receptor (nAChR) ligand that binds to the ventral and rostral ventrolateral tegmental areas of the brain. It has been shown to have an excitatory effect in animal models and was found to increase locomotor activity in rats. TCS-OX2-29 has been evaluated for its potential interaction with other compounds, including nicotine, which is used as a model for nAChR agonists. TCS-OX2-29 has been shown to be effective at doses of 20 mg/kg or higher when administered chronically over a period of ten days.
Propriedades químicas
Consulta técnica sobre: 3D-XPA52375 TCS-OX2-29
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.
